Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues
A major scandal in Japan over the Novartis hypertension drug valsartan has resulted in a retraction from the Journal of Human Hypertension. Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest. Also that year, … Continue reading Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues